NCT06133816 is a NA clinical trial of Framed Introductory Message A in Lung Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

Who is sponsoring NCT06133816?

NCT06133816 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT06133816?

Interventions in NCT06133816: Framed Introductory Message A, Framed Introductory Message B, Framed Introductory Message C, Framed Tobacco Use Message A, Framed Tobacco Use Message B, Financial Incentive.

What condition does NCT06133816 study?

NCT06133816 studies Lung Cancer.

Is NCT06133816 still recruiting?

NCT06133816 is currently completed. Last updated 31 May 2025.

Are results published for NCT06133816?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-31 · How we verify

NCT06133816

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lung Cancer Screening Eligibility Assessment

Completed NA Results posted Last updated 31 May 2025

What this trial tests

NA trial testing Framed Introductory Message A in Lung Cancer in 6,125 participants. Completed in 31 January 2024.

Timeline

31 July 2023

Primary endpoint
31 January 2024

31 January 2024

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	single
Primary purpose	health services research
Enrollment	6,125
Start date	31 July 2023
Primary completion	31 January 2024
Estimated completion	31 January 2024
Sites	1 location across United States

Drugs / interventions tested

Framed Introductory Message A
Framed Introductory Message B
Framed Introductory Message C
Framed Tobacco Use Message A
Framed Tobacco Use Message B
Financial Incentive

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

Adults 50 to 80, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Full Survey Completion Primary · 7 days

The proportion of participants that answers all three survey questions via text message among all those randomized.

Group	Value	95% CI
Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive)	358
Arm 2 (Introductory Message A + Tobacco Use Message A)	381
Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive)	383
Arm 4 (Introductory Message A + Tobacco Use Message B)	389
Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive)	372
Arm 6 (Introductory Message B + Tobacco Use Message A)	399
Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive)	386
Arm 8 (Introductory Message B + Tobacco Use Message B)	402
Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive)	335
Arm 10 (Introductory Message C + Tobacco Use Message A)	397
Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive)	373
Arm 12 (Introductory Message C + Tobacco Use Message B)	366

Partial Survey Completion Secondary · 7 days

The proportion of participants that answer at least one of three survey questions via text message among all those randomized.

Group	Value	95% CI
Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive)	377
Arm 2 (Introductory Message A + Tobacco Use Message A)	405
Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive)	394
Arm 4 (Introductory Message A + Tobacco Use Message B)	403
Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive)	381
Arm 6 (Introductory Message B + Tobacco Use Message A)	414
Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive)	403
Arm 8 (Introductory Message B + Tobacco Use Message B)	408
Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive)	345
Arm 10 (Introductory Message C + Tobacco Use Message A)	413
Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive)	383
Arm 12 (Introductory Message C + Tobacco Use Message B)	385

Sponsor's own description

The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

University of Pennsylvania Telehealth Research Center of Excellence.
Wainwright JV, Aggarwal C, Beucker S, Dougherty DW, et al · · 2024 · cited 1× · PMID 38924794 · DOI 10.1093/jncimonographs/lgae011

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06133816 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 31 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06133816.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing